ClinicalTrials.gg
WithdrawnNCT06795399Updated Apr 17, 2026

A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure

A Phase 2 interventional study of OPC-131461 and Placebo in Heart Failure, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
No sites were initiated, no sites were activated, no patients were enrolled in this study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Heart Failure · Otsuka Holdings Co., Ltd..

Enrollment
16th of 16
0 · median 81
Started
2025
the only one that year
Phase 2
6 of 17
none open now
Registered
17th of 17
by date

Among the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd., this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 2, and was the 17th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. is open now. The open studies under Heart Failure, anywhere →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies in Heart Failure by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

The primary objective of the study is to compare relative changes in blood N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels after 30 days of treatment in participants with worsening heart failure (WHF), who are treated with either OPC-131461 or placebo.

Read the detailed description

Each participant in this trial is expected to participate in the following periods of the trial:

  • Screening/qualification period: up to 48 hours (2 days)
  • Double-blind treatment period: 30 days
  • Safety follow-up period: 7 days
  • Vital status follow-up period: 6 months

Eligible participants will be randomized to receive the study drug (1 of 2 dose levels [5 milligrams (mg) or 10 mg] of OPC-131461 tablets or placebo) in a 1:1:1 ratio.

Overall, the trial duration is expected to be approximately 210 days (7 months).

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HF ≥ 3 months prior to screening.
  • Admitted to the hospital with primary diagnosis of WHF and received treatment with intravenous (IV) diuretics.
  • Eligible participants will be randomized no earlier than 48 hours and up to 5 days after presentation to the hospital as long as they meet the following definition of stable status: Stable for at least 24 hours, defined by systolic blood pressure (SBP) ≥ 90 millimeters of mercury (mmHg) for preceding 24 hours, no increase in diuretic dose for 24 hours prior to randomization, did not receive IV inotropic or vasodilator (including nitrates) for 24 hours prior to randomization, and no oxygen therapy or mechanical ventilation in the 24 hours prior to randomization
  • (LVEF) assessed either during hospitalization for Index Event or within 12 months prior to randomization.
  • Has evidence of incomplete decongestion, indicated by NT-proBNP levels > 750 picograms per milliliter (pg/mL) (or > 1000 pg/mL if in atrial fibrillation). At hospital sites where NT proBNP test is unavailable at screening: B-type natriuretic peptide (BNP) > 375 pg/mL (or > 500 pg/mL if in atrial fibrillation).

Exclusion criteria

Exclusion Criteria:

  • Primary cause of WHF (Index Event) due to valvular heart disease (defined as severe aortic or primary mitral regurgitation, moderate or severe aortic stenosis, any mitral stenosis requiring surgical repair, or active endocarditis), congenital heart disease, hypertrophic obstructive cardiomyopathy, pulmonary embolism, Type I myocardial infarction, infection, severe anemia, exacerbation of (COPD), or sustained ventricular tachycardia, or bradycardia with sustained ventricular rate \< 45 beats/minute.
  • Duration of hospitalization for Index Event > 2 weeks at time of screening.
  • End-stage HF requiring at the time of screening left ventricular assist device (LVAD), intra-aortic balloon pump (IABP) or any similar mechanical support.
  • Cardiac surgery (coronary artery bypass grafting [CABG]), percutaneous coronary intervention (PCI), implantation of a cardiac device or cardiac mechanical support implantation within 30 days prior to randomization or planned during the study
  • Severely impaired renal function \< 25 milliliters per minute per 1.73-meter square (mL/min/1.73m\^2).
  • History of dialysis or kidney transplant.
  • History of cirrhosis or noncirrhotic portal hypertension.
  • Severe hyponatremia Sodium (Na) level \< 125 mEq/L (milliequivalents per liter) or hypernatremia Na level > 145 mEq/L).
  • Systolic blood pressure \< 90 mmHg at screening.
  • History of or current hepatitis or acquired immunodeficiency syndrome or carriers of surface antigen (HBsAg) and/or antibodies (anti-HCV), or (HIV) antibodies.
  • History of any significant drug allergy or known or suspected to any component of the study drug.
  • Use of any drug within 30 days prior to screening.
  • History of serious mental disorders that, in the opinion of the investigator, would exclude the participant from participating in this trial.

Note: Other protocol-specified inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    OPC-131461 5 mg

    Participants will receive OPC-131461 5 mg, orally, once daily for 30 days.

    Drug: OPC-131461

  • Experimental
    OPC-131461 10 mg

    Participants will receive OPC-131461 10 mg, orally, once daily for 30 days.

    Drug: OPC-131461

  • Placebo comparator
    Placebo

    Participants will receive OPC-131461 matched placebo, orally, once daily for 30 days.

    Drug: Placebo

Interventions

  • DrugOPC-131461

    OPC-131461 will be administered as oral tablets.

  • DrugPlacebo

    OPC-131461 matched placebo will be administered as oral tablets.

06

What researchers measure

Primary outcomes

  1. Proportional Change From Baseline in Serum Concentration of NT-proBNP at Day 31

    Proportional change from baseline in serum concentration of NT-proBNP is defined as the ratio of NT-proBNP at Day 31 over baseline.

    Time frame: Baseline, Day 31

Secondary outcomes

  1. Proportional Change From Baseline in Serum Concentration of NT-proBNP at Days 8 and 15

    Proportional change from baseline in serum concentration of NT-proBNP is defined as the ratio of NT-proBNP at Day 8 over baseline and at Day 15 over baseline.

    Time frame: Baseline, Days 8 and 15

  2. Time to First Heart Failure (HF) Rehospitalization

    Time frame: From first dose of study drug up to end of treatment period (up to 30 days)

  3. Time to First Urgent HF Outpatient Visit

    Time frame: From first dose of study drug up to end of treatment period (up to 30 days)

  4. Time to Cardiovascular (CV) Death

    Time frame: From first dose of study drug up to end of treatment period (up to 30 days)

  5. Composite Endpoint Defined by the Win Ratio

    A hierarchical composite of CV death, number of HF rehospitalizations, number of urgent HF outpatient visits, time to first HF rehospitalization or urgent HF outpatient visit, and change from baseline in Kansas City Cardiomyopathy Questionnaire - 23 items (KCCQ-23) Total Symptom Score (difference larger or equal to 5) will be analyzed using the Win ratio method.

    Time frame: From the first dose of the study drug up to end of treatment period (up to 30 days)

  6. Change From Baseline in Kansas City Cardiomyopathy Questionnaire - 23 items (KCCQ-23) Clinical Summary Score

    The KCCQ-23 is a questionnaire consisting of 23 items to measure health status, symptoms, and quality of life in participants with heart failure. The KCCQ-23 consists of the following domains: Physical Limitation, Symptoms, Self-efficacy and knowledge, Quality of Life, Social Limitation. A functional status score is calculated from physical limitations and symptoms. The clinical summary score is derived from the functional status score, quality of life, and social limitations domains and range from 0-100. A higher score indicates fewer symptoms and better physical functioning, reflecting improved overall clinical status.

    Time frame: Up to 31 days

  7. Change From Baseline in KCCQ-23 Total Symptom Score

    The KCCQ-23 is a questionnaire consisting of 23 items to measure health status, symptoms, and quality of life in participants with heart failure. The KCCQ-23 consists of the following domains: Physical Limitation, Symptoms, Self-efficacy and knowledge, Quality of Life, Social Limitation. The total symptom score combines responses from the symptom frequency and symptom burden domains. Score ranges from 0-100, where higher scores indicate fewer symptoms and a better symptom experience.

    Time frame: Up to 31 days

  8. Change From Baseline in KCCQ-23 Physical Limitations Score

    The KCCQ-23 is a questionnaire consisting of 23 items to measure health status, symptoms, and quality of life in participants with heart failure. The KCCQ-23 consists of the following domains: Physical Limitation, Symptoms, Self-efficacy and knowledge, Quality of Life, Social Limitation. The Physical Limitation Score will assess the impact of HF on participants' ability to perform physical activities. Scores range from 0-100, with higher scores reflecting fewer physical limitations and better functional capacity.

    Time frame: Up to 31 days

  9. Change From Baseline in Body Weight

    Time frame: Up to 37 days

  10. Change From Baseline in EVEREST Congestion Score

    The EVEREST Congestion Score will assess the severity of congestion in participants with HF. The score includes clinical signs and symptoms such as edema, dyspnea, orthopnea, jugular vein distention, rales, and fatigue. The total score ranges from 0-18, with a higher score indicating greater severity of congestion and a lower score reflecting less congestion and improvement in symptoms.

    Time frame: Up to 37 days

  11. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Up to 37 days

  12. Number of Participants With Serum Electrolyte Abnormalities

    Time frame: Up to 37 days

  13. Number of Participants With Hypotension/Orthostatic Hypotension and Related Treatment-emergent Adverse Events (TEAEs) of Syncope and Presyncope

    Time frame: Up to 37 days

  14. Number of Participants With Major and Minor Bleeding Events

    Time frame: Up to 37 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in May 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2025
First posted
Jan 28, 2025
StartActual
Apr 30, 2025
Primary completionActual
May 25, 2025
CompletionActual
May 25, 2025
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06795399
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Apr 30, 2025
Primary completion
May 25, 2025
Completion
May 25, 2025
Last update
Apr 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion